The obesity epidemic: Current and future pharmacological treatments

被引:67
作者
Hofbauer, Karl G. [1 ]
Nicholson, Janet R.
Boss, Olivier
机构
[1] Univ Basel, Biozentrum Pharmazentrum, CH-4056 Basel, Switzerland
[2] Sirtris Pharmaceut Inc, Cambridge, MA 02139 USA
关键词
appetite; satiety; energy balance; adipose tissue; drugs;
D O I
10.1146/annurev.pharmtox.47.120505.105256
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The unabated rise in the prevalence of obesity is a challenge for global health care systems. Efforts to reverse this trend by dietary or behavioral counseling have not been successful, which has stimulated efforts to find a role for pharmacotherapy. Currently only a small number of antiobesity drugs are approved for long-term use and only a few compounds are in clinical development. Despite recent progress in the understanding of the regulation of energy balance, drug discovery has been less productive than expected. In the present review, the clinically available antiobesity agents are discussed. Examples of drug candidates that are currently in development are given and the possible future range of antiobesity agents is illustrated by the targets being addressed in drug discovery. Finally, the efficacy of antiobesity agents and their value in the treatment of obesity are assessed in comparison with other therapeutic approaches, such as surgery and changes in lifestyle.
引用
收藏
页码:565 / 592
页数:28
相关论文
共 131 条
[81]   Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity [J].
Lambert, PD ;
Anderson, KD ;
Sleeman, MW ;
Wong, V ;
Tan, J ;
Hijarunguru, A ;
Corcoran, TL ;
Murray, JD ;
Thabet, KE ;
Yancopoulos, GD ;
Wiegand, SJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (08) :4652-4657
[82]   How obesity causes diabetes: Not a tall tale [J].
Lazar, MA .
SCIENCE, 2005, 307 (5708) :373-375
[83]   CHANGES IN ENERGY-EXPENDITURE RESULTING FROM ALTERED BODY-WEIGHT [J].
LEIBEL, RL ;
ROSENBAUM, M ;
HIRSCH, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (10) :621-628
[84]   Meta-analysis: Pharmacologic treatment of obesity [J].
Li, ZP ;
Maglione, M ;
Tu, WL ;
Mojica, W ;
Arterburn, D ;
Shugarman, LR ;
Hilton, L ;
Suttorp, M ;
Solomon, V ;
Shekelle, PG ;
Morton, SC .
ANNALS OF INTERNAL MEDICINE, 2005, 142 (07) :532-546
[85]   Calorie restriction extends yeast life span by lowering the level of NADH [J].
Lin, SJ ;
Ford, E ;
Haigis, M ;
Liszt, G ;
Guarente, L .
GENES & DEVELOPMENT, 2004, 18 (01) :12-16
[86]   Meta-analysis: Surgical treatment of obesity [J].
Maggard, MA ;
Shugarman, LR ;
Suttorp, M ;
Maglione, M ;
Sugarman, HJ ;
Livingston, EH ;
Nguyen, NT ;
Li, ZP ;
Mojica, WA ;
Hilton, L ;
Rhodes, S ;
Morton, SC ;
Shekelle, PG .
ANNALS OF INTERNAL MEDICINE, 2005, 142 (07) :547-559
[87]   Modulation of neuropeptide Y expression in adult mice does not affect feeding [J].
Marie, LS ;
Luquet, S ;
Cole, TB ;
Palmiter, RD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (51) :18632-18637
[88]   Antiobesity effect of a melanin-concentrating hormone 1 receptor antagonist in diet-induced obese mice [J].
Mashiko, S ;
Ishihara, A ;
Gomori, A ;
Moriya, R ;
Ito, M ;
Iwaasa, H ;
Matsuda, M ;
Feng, Y ;
Shen, Z ;
Marsh, DJ ;
Bednarek, MA ;
MacNeil, DJ ;
Kanatani, A .
ENDOCRINOLOGY, 2005, 146 (07) :3080-3086
[89]   Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease [J].
Matsuzawa, Y .
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE, 2006, 3 (01) :35-42
[90]   Metabolic syndrome: A clinical and molecular perspective [J].
Moller, DE ;
Kaufman, KD .
ANNUAL REVIEW OF MEDICINE, 2005, 56 :45-+